FDA Accepts BioCardia's Helix Catheter Pre-Submission, Review Scheduled for Early Q2
Summary
BioCardia announced that the FDA has accepted its pre-submission package for the Helix Transendocardial Delivery Catheter, with a substantive review and meeting scheduled for early Q2. This is a positive regulatory step for a device that the company's CEO states is meaningful for the entire field of cardiac cell, gene, and protein therapeutics. The Helix catheter is also expected to enhance the approval process for BioCardia's CardiAMP Cell Therapy, which previously received Breakthrough Designation. For a micro-cap biotech, this progress in the regulatory pathway for a key enabling device is a material development. Traders will now watch for the outcome of the FDA's review and meeting in early Q2 for further updates on potential marketing clearance.
At the time of this announcement, BCDA was trading at $1.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.5M. The 52-week trading range was $1.00 to $3.20. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.